⌘+K

Update Note

Withdrawing fair value following rights issue announcement - Correction

Maria Karlsson Osipova

2026-04-21

20:45 CEST

Following the announcement of the rights issue, we withdraw our fair value range on Elicera Therapeutics, as DNB Carnegie is acting as an advisor to the company. Our estimates have not been updated and should no longer be relied upon.

Partially underwritten rights issue. This morning, Elicera Therapeutics announced a partially underwritten (75% covered by subscription commitments and guarantee undertakings) rights issue, subject to approval at an EGM scheduled for 8 May. The rights issue will comprise up to c24m new shares at a subscription price of SEK3.0 per share; the subscription period runs from 15 to 29 May 2026. If fully subscribed, the company will raise ~SEK73m, corresponding to net proceeds of ~SEK63m after transaction costs. Non-participating shareholders will face dilution of ~33%.

Proceeds earmarked to support pipeline execution. According to the company, the net proceeds will primarily be used for recruitment and treatment of all 18 patients in the CARMA study (c40%), advance preparations for the planned Phase I/Ib trial of ELC-401 (c30%), and to support general corporate purposes (c30%). It expects the proceeds to fund operations until the end of 2028. In parallel, Elicera Therapeutics is pursuing several opportunities to secure non-dilutive (“soft”) funding through grant applications from various sources. Responses to these applications are expected throughout 2026 and will potentially help support the funding of the planned clinical trial for ELC-401, the company stated.

Correction: This report was updated to add the correct disclaimers. There are no other changes to report content. The original report was published 21 April 2026, 11:04 CET.

Sweden

Healthcare

Latest share price

SEK

2.5

0.20%

18 Nov 2026 14:32 CET

Fair value range

SEK

6.0

—

10.0

3 Jul 2026

Market cap

SEK

162

m

Next report

Q3

27 Nov 2026

Key stats

Year

2026e

EPS

-0.43

EPS (Adj.)

-0.43

Sales Growth

EPS Growth (Adj.)

P/E

P/E (Adj.)

EV/EBITA

-4.5

EV/EBITDA

-4.5

Learn more

About DNB Carnegie Access

DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

Private Banking

Tailored wealth management. Your financial future, personalized.

Montrose

A digital investment platform designed for passionate investors.

DNB Carnegie

Leading Nordic investment bank and wealth management.

© Copyright DNB Carnegie Investment Bank AB